Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System
Authors
Keywords
-
Journal
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
Volume 26, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-02-15
DOI
10.3389/jpps.2023.11235
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data
- (2022) Ming Ni et al. Frontiers in Pharmacology
- Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
- (2022) Michele Fusaroli et al. DRUG SAFETY
- Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database
- (2021) Sifu Huang et al. Journal of Zhejiang University-SCIENCE B
- Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
- (2021) Michiel S. van der Heijden et al. EUROPEAN UROLOGY
- Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
- (2021) Thomas A. Wichelmann et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
- (2021) Hye Jung Cho et al. Annals of Coloproctology
- Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database – A Case Study
- (2021) Mario Gaio et al. Frontiers in Pharmacology
- Management of VEGFR-Targeted TKI for Thyroid Cancer
- (2021) Tomohiro Enokida et al. Cancers
- Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
- (2021) Timothée Olivier et al. JAMA Network Open
- Borrowing external information to improve Bayesian confidence propagation neural network
- (2020) Keisuke Tada et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance
- (2020) Goeun Park et al. Life-Basel
- Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional
- (2020) Patricia Sanz-Segura et al. Gastroenterologia y Hepatologia
- Management of treatment-related toxicities in advanced medullary thyroid cancer
- (2019) Venessa H.M. Tsang CURRENT OPINION IN ONCOLOGY
- Severe Gastrointestinal Toxicity of MEK Inhibitors
- (2019) Nadim Mourad et al. MELANOMA RESEARCH
- Clinical Features of Rituximab-associated Gastrointestinal Toxicities
- (2019) Niharika Mallepally et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- “Immune checkpoint inhibitor-related luminal GI adverse events”
- (2019) Paul T. Kröner et al. GASTROINTESTINAL ENDOSCOPY
- Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs
- (2018) Ingvar Bjarnason et al. GASTROENTEROLOGY
- Enterocolitis due to immune checkpoint inhibitors: a systematic review
- (2018) Emilie Soularue et al. GUT
- Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA
- (2018) Chisato Fukazawa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer
- (2017) Emi Date et al. INVESTIGATIONAL NEW DRUGS
- DrugBank 5.0: a major update to the DrugBank database for 2018
- (2017) David S Wishart et al. NUCLEIC ACIDS RESEARCH
- Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
- (2017) Franck Carbonnel et al. Seminars in Immunopathology
- The benefits of data mining
- (2017) Audrey Bone et al. eLife
- Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials
- (2016) Zexing Wang et al. JOURNAL OF CHEMOTHERAPY
- Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
- (2016) David Cella et al. LANCET ONCOLOGY
- Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review
- (2016) Florence Gass-Jégu et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases
- (2015) Kaori Nomura et al. Drug Design Development and Therapy
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis
- (2014) Sigrid Narum et al. BMJ Open
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers
- (2012) Taher Abu-Hejleh et al. Current Oncology Reports
- Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation
- (2009) Agustin Cornejo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- The late adverse events of rituximab therapy – rare but there!
- (2009) Ron Ram et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started